Journal of Oncology / 2010 / Article / Tab 3

Clinical Study

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

Table 3

Number of patients who experienced a grade 3 or 4 toxicity.

NCI-CTCAE grade 3-4 toxicityGrade 3Grade 4

Hematological toxicity
 Anemia3 (7.0%)1 (2.3%)
 Leucopenia1 (2.3%)2 (4.7%)
 Neutropenia5 (11.6%)3 (7.0%)
 Thrombocytopenia1 (2.3%)0 (0.0%)

Nonhematological toxicity
 Fatigue9 (20.5%)0 (0.0%)
 Nausea2 (4.5%)0 (0.0%)
 Diarrhea5 (11.4%)1 (2.3%)
 Vomiting3 (6.8%)0 (0.0%)
 Anorexia2 (4.5%)0 (0.0%)
 Mucositis/stomatitis2 (4.5%)0 (0.0%)
 Dehydration2 (4.5%)0 (0.0%)
 Febrile neutropenia1 (2.3%)0 (0.0%)
 Infection0 (0.0%)1 (2.3%)
 Rash1 (2.3%)0 (0.0%)
 Biochemistry
 ALAT increase4 (9.5%)0 (0.0%)
 Hyperbilirubinemia2 (4.8%)0 (0.0%)
 Hypokalemia2 (4.8%)0 (0.0%)
 Alkaline phosphatase1 (2.4%)0 (0.0%)
 Hyponatremia1 (2.4%)0 (0.0%)

Abbreviations: NCI-CTCAE: National Cancer Institute-Common Terminology Criteria for Adverse Events; ALAT: alanine aminotransferase.